Portal de investigación
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Roddie, Claire
- Sandhu, Karamjeet Singh
- Tholouli, Eleni
- Shaughnessy, Paul
- Barba, Pere
- Yallop, Deborah
- Abedi, Mehrdad
- Chaganti, Sridhar
- Ghobadi, Armin
- Yared, Jean
- Logan, Aaron
- Bishop, Michael Russell
- Zhang, Michael
- Brugger, Wolfram
- Pule, Martin
- Park, Jae H.
- DeAngelo, Daniel J.
- Jabbour, Elias
- FELIX Investigators
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Roddie,C,Sandhu,KS,Tholouli,E,Shaughnessy,P,Barba,P,Guerreiro,MN,Yallop,D et al. Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2023.